Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Kazia Therapeutics (NASDAQ: KZIA) said it will expand its ongoing Phase 1b trial of paxalisib plus standard-of-care therapy in advanced triple-negative breast cancer. Planned enrollment will rise from 12 to 36 patients, based on continued safety, tolerability and early clinical activity. The larger dataset is expected to better assess ORR, PFS and biomarkers with pembrolizumab and chemotherapy.
How this was made
The 30-second read
Why it matters
Increasing enrollment from 12 to 36 should improve the quality of preliminary efficacy and translational biomarker assessment (ORR, PFS), while continued emphasis on safety/tolerability reduces near-term clinical risk perception.
Market read
A clinical-stage biotech milestone (larger Phase 1b cohort) that can improve the odds of more informative efficacy/biomarker updates, supporting incremental valuation momentum.
What to watch
Abstract withdrawal for IP reasons may reduce near-term visibility at ASCO 2026, potentially muting sentiment despite the trial expansion.
Background
Kazia is running a Phase 1b study of paxalisib (PI3K/Akt/mTOR inhibitor) combined with pembrolizumab and chemotherapy in advanced triple-negative breast cancer, with prior preclinical support and multiple ongoing paxalisib programs.
Ticker impact
Kazia plans to expand its Phase 1b paxalisib + pembrolizumab + chemotherapy trial in advanced TNBC from 12 to 36 patients.
Near-term: modest positive bias on trial momentum; medium-term: upside contingent on forthcoming clinical updates through 2026–2027.
The news is a clinical development milestone (bigger dataset) without new efficacy numbers, but it reduces uncertainty around tolerability and improves statistical power for response/biomarker assessment.
Market effects
Supports read-across optimism for PI3K/mTOR pathway inhibitors and combination immunotherapy strategies in TNBC, though evidence remains early-stage.
Primarily impacts US-listed small/mid-cap biotech sentiment; limited direct regional spillover beyond clinical-trial peers.
Global oncology investors may view the expansion as incremental validation of paxalisib’s translational rationale, but no cross-border regulatory decision is announced.
Counterpoint
Enrollment expansion can also reflect operational needs or slower accrual rather than a step-change in efficacy; without new ORR/PFS data, upside may be capped.
Key entities
- companyKazia Therapeutics
Expanding Phase 1b enrollment for paxalisib-based combination therapy in advanced TNBC.
- drugpaxalisib
Investigational brain-penetrant PI3K/Akt/mTOR pathway inhibitor being tested in combination regimens.
- drugpembrolizumab
Checkpoint inhibitor used in combination with paxalisib and chemotherapy in the trial.
